References
- 1. Abu-Amer Y., Darwech I.: Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies. Arthritis Res Ther 2007, 9 (Suppl 1), S6.
- 2. Åstrand J., Aspenberg P.: Reduction of instabilityinduced bone resorption using bisphosphonates. High doses are needed in rats. Acta Orthop Scand 2002, 73, 24-30.
- 3. Bexheti D., Anderson E.I., Hutt A.J., Brown M.A.: Evaluation of multidimensional capillary electrophoretic methodologies for determination of amino bisphosphonate pharmaceuticals. J Chromatograph A 2006, 1130, 137-14.
- 4. Bock O., Börst H., Beller G., Armbrecht G., Degner C., Martus P., Roth H.J., Felsenberg D.: Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT. Bone 2012, 50, 317-24.
- 5. Daley-Yates P., Gifford L., Hoggarth C.: Assay of 1- hydroxy-3-aminopropylidene-1,1-bisphosphonate and related bisphosphonates in human urine and plasma by high-performance ion chromatography. J Chromatogr B: Biomed Sci Appl 1989, 490, 329-338.
- 6. Fleisch H.: Bisphosphonates: mechanisms of action. Endcrinol Rev 1998, 19, 80-102.
- 7. Frith J.C., Monkkonen J., Blackburn G.M., Russell R.G., Rogers M.J.: Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5’-(β, γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997, 12, 1358-1367.
- 8. Gao Y., Zou S., Liu X., Bao Ch., Jing H.: The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats. Biomaterials 2009, 30, 1790-1796.
- 9. Geoffroy V., Paschalis E.P., Libouban H., Blouin S., Ostertag A., Chappard D., Cros M., Phipps R., de Vernejoul M.C.: Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures. Calcif Tissue Int 2011, 88, 464-475.
- 10. Goldring S.R., Gravallese E.M.: Bisphosphonates: environmental protection for the joint? Arthritis Rheum 2004, 50, 2044-2047.
- 11. Goodship A.E., Blunn G.W., Green J., Coathup M.J.: Prevention of strain-related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate. J Orthop Res 2008, 26, 693-703.
- 12. Huikko K., Kostiainen R.: Development and validation of a capillary zone electrophoresis method for the determination of bisphosphonate and phosphonate impurities in clodronate. J Chromatogr A 2000, 893, 411-420.
- 13. Jakobsen T., Bass J., Bechtold J.E., Elmengaard B., Soballe K.: Soaking morselized allograft bone in bisphosphonate can impair implant fixation. Clin Orthop 2007, 463, 195-201.
- 14. Jia H.J., Li W., Zhao K.: Determination of risedronate in rat plasma samples by ion-pair high-performance liquid chromatography with UV detector. Anal Chim Acta 2006, 562, 171-175.
- 15. Kwong E., Chiu A.M.Y., McClintock S.A., Cotton M.L.: HPLC analysis of an amino bisphosphonate in pharmaceutical formulations using post-column derivatization and fluorescence detection. J Chromatogr Sci 1990, 28, 563-566.
- 16. Lewis G., Janna S.: Aldendronate in bone cement. Clin Orthop Rel Res 2006, 445, 233-238.
- 17. Makkonen N., Hirvonen M-R., Teräväinen T., Savolainen K., Mönkönen J.: Different effects of three bisphosphonates on nitric oxide production by Raw 264 macrophage-like cells in vitro. J Pharm Exp Ther 1996, 277, 1097-1102.
- 18. Marx R.E.: Pamidronate (Aredia) and zoledronate (Zometa) induced a vascular necrosis of the jaw: a growing epidemic. J Oral Maxillofac Surg 2003, 61, 1115-1117.
- 19. Matuszewski Ł., Matuszewska A., Mazurkiewicz T., Rogalski J., Cho N.S., Ohga S.: Determination of bisphosphonates by ion-pair HPLC. J Fac Agr Kyushu Univ 2011, 56, 213-216.
- 20. Matuszewski Ł, Turżańska K, Matuszewska A, Jabłoński M, Polkowska I, Mazurkiewicz T.: Effect of implanted bisphosphonate-enriched cement on the trabecular microarchitecture of bone in a rat model using microcomputed tomography. International Orthopaedics. http://www.springer.com/alert/urltracking.do?id=Lfb8d2bMbe6f65Saad8ca1. Accessed 24 February 2013.
- 21. Mazurkiewicz T., Matuszewski Ł., Matuszewska A., Jaszek M.: Implanted bisphosphonates in bone cement affect bone markers in rat serum. International Orthopaedics. http://link.springer.com/article/10.1007/s00264-013-1816-6. Accessed 26 January 2013.
- 22. Migliorati C.A.: Bisphosphonates and oral cavity bone necrosis. J Clin Oncol 2003, 21, 4253-4254.
- 23. Morris C.D., Einhorn T.A.: Bisphosphonates in orthopedic surgery. J. Bone Joint Surg 2005, 87, 1609-1618.
- 24. Perjesi P., Kim T., Zharikova A.D., Li X., Ramesh T., Ramasubbu J., Prokai L.: Determination of clodronate content in liposomal formulation by capillary zone electrophoresis. J Pharma Biomed Anal 2003, 31, 929-935.
- 25. Peter B., Gauthier O., Laib S., Bujoli B., Guicheux J., Janvier P.: Local delivery of bisphosphonate from coated orthopedic implants increases implant mechanical stability in osteoporotic rats. J Biomed Mater Res A 2006, 76, 133-143.
- 26. Prieto-Alhambra D., Javaid M., Judge A., Murray D., Carr A., Cooper C., Arden N.: Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study. BMJ 2011. http://dx.doi.org/10.1136/bmj.d722.
- 27. Rodriquez J.A.B., Desimone M.F., Iglesias S.L., Giorgieri S.A., Diaz L.E.: Validation of a capillary electrophoresis method for the analysis of ibandronate related impurities. J Pharm Biomed Anal 2007, 44, 305-308.
- 28. Russell R.G.G., Rogers M.J.: Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999, 25, 97-106.
- 29. Schindeler A., Birke O., Yu N.Y., Morse A., Ruys A., Baldock P.A., Little D.G.: Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate. J Bone Joint Surg Br 2011, 93, 1134-1139.
- 30. Sirén H., Määttänen A., Riekkola M.L.: Determination of small anions by capillary electrophoresis using indirect UV detection with sulphonated nitrosonaphtol dyes. J Chromatogr A 1997, 767, 293-301.
- 31. Sparidans R.W., Hartigh J.: Chromatographic analysis of bisphosphonates. Pharm World Sci 1999, 21, 1-10.
- 32. Tomlin J.L., Sturgeon C., Pead M.J., Muir P.: Use of bisphosphonate drug aldendronate for palliative management of osteosarcoma in two dogs. Vet Rec 2000, 147, 129-132.
- 33. Wilkinson J.M., Little D.G.: Bisphosphonates in orthopedic applications. Bone 2011, 49, 95-102.
- 34. Viereck V., Emons G., Lauck V., Frosch K.H., Blaschke S., Grundker C., Hofbauer L.: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002, 291, 680-668.
- 35. Xie Z.X., Jiang Y., Zhang D.Q.: Simple analysis of four bisphosphonates simultaneously by reverse phase liquid chromatography using n-amylamine as volatile ion- pairing agent. J Chromatogr 2006, 1104, 173-178.
- 36. Xuenong Z., Qingyun X., Haishengen L., Bunger M., Lind M., Bunger C.: Effect of alendronate on bone in growth into porous tantalum and carbon fiber interbody devices. Acta Orthop Scand 2003, 74, 596-603.
- 37. Zacharis C.K., Tzanavaras P.D.: Determination of bisphosphonate active pharmaceutical ingredients in pharmaceuticals and biological material: A review of analytical methods. J Pharma Biomed Anal 2008, 48, 483-496.